Optimization and validation of high-performance liquid chromatography using modified QuEChERS to determine anthelmintic drugs in mutton.

The aim of this study was to rapidly determine the presence of anthelmintic drugs in sheep meat using the optimized high-performance liquid chromatography-ultraviolet (HPLC-UV) method with modified QuEChERS (quick, easy, cheap, effective, rugged, safe) technology. Fifty fresh sheep meat samples from different slaughterhouses were collected. A double extraction procedure (QuEChERS/HPLC-UV technology) was used to extract the target analytes. A multilevel calibration curve from 1 to 1000 g/kg was used to establish instrument linearity for rafoxanide, albendazole, and closantel, whereas 0.1-100 µg/kg was used for ivermectin, levamisole, and oxyclozanide to find the lowest concentration, maximum residue limit (MRL), and occupied range for targeted analytes. The concentration levels were used to investigate the linearity, whereas several certified reference materials were applied to determine accuracy. The process was linear for all combinations, from the limit of quantification (LOQ) to the maximum concentration. The LOQ was established at 0.5 µg/kg for ivermectin, levamisole, and oxyclozanide and 10 µg/kg for rafoxanide, albendazole, and closantel. Recovery values were 70%-120%, and repeatability/reproducibility stated in relative standard deviation was obtained at less than 20%. QuEChERS method revealed that most meat samples contained anthelmintic drug residues, of which the majority exceeded the MRLs. Thus, the drugs should be used correctly in animals to avoid residues in food for human consumption.

Dissipation, processing factors and dietary risk assessment of the bioinsecticide abamectin in herbal plants belonging to Lamiaceae family from open field to herbal tea infusion.

Abamectin, the mixture of avermectin B1a and B1b, is widely used as a bioinsecticide and is an alternative to chemical pest control from insects. To our knowledge, its behaviour is not fully recognized, especially in herbs. Thus, the objective of this study was to investigate the environmental fate of abamectin in herbal plants belonging to the Lamiaceae family, its dissipation in open field studies laboratory processing treatments and dietary risk assessment. Three medicinally and culinary important species of herbs: Melissa officinalis L., Mentha × piperita L. and Salvia L. were treated with single and double dose than recommended on the label during their cultivation (BBCH 11-29). Residues were monitored using the QuEChERS method followed by the LC-MS/MS. The dissipation pattern of the sum of avermectin B1a and B1b and their persistence were observed 14 d after spraying. Abamectin decline was very rapid in plants and followed the first-order kinetics model. The half-life (t1/2) was in the range of 0.96-1.08 d (single dose) and 0.93-1.02 d (double dose). The pre-harvest intervals (decrease to the level of 0.01 mg kg-1) were 7.29-7.92 d at single and 7.99-8.64 d at double dose application. Herbal infusion preparation in previously washed and dried mint, lemon balm and sage leaves was the key processing step in the removal of abamectin residues. The reduction of initial deposits after single dose treatment was noted up to 65% (PF = 0.35-0.67) and up to 79% after double dose application (PF = 0.21-0.72) in herbal tea. Acute risk assessment of children and adults for the highest residues in EFSA PRIMo model at single and double dose expressed as hazard quotients (HQ) were <1, indicating no risk to humans via consumption of the herbal products. The data provide a better understanding of abamectin behaviour in herbal plants and can help assure herbs' safety for consumers.

Smartphone-assimilated colorimetric sensor for sub-nanomolar emamectin detection via KA30 capped silver nanoparticles in food, bio-fluids and water samples.

In this report, we firstly synthesized nitro calix [4] resorcinarene compound (referred as KA30) and characterized it though proton (1H) nuclear magnetic resonance (NMR) spectroscopy, electrospray ionization mass spectrometry (ESI-MS) and Fourier Transform Infra-red (FTIR) spectroscopy. KA30 was applied as functionalizing agent for the formation of silver nanoparticles (KA30-AgNPs). These NPs were confirmed as highly selective and extremely sensitive colorimetric sensor for ultra-low level detection of emamectin (EMA) as a novel report. Significant aspect of the sensor is its unique detection range between 0.0005 and 29.5 µM via color change from yellow to colorless with hypochromic-bathochromic shift exhibiting limit of detection (LOD) and limit of quantification (LOQ) as 0.12 nM and 0.4 nM respectively. The sensor was applied to colorimetrically and optically detect EMA in real samples of serum, urine and food. The sensor was further allied with smartphone for real-time, and on-site detection of EMA and results were validated through UPLC.

Lab-made CO2 laser-engraved electrochemical sensors for ivermectin determination.

The ivermectin (IVM), as a broad-spectrum antiparasitic drug, was widely prescribed to treat COVID-19 during the pandemic, despite lacking proven efficacy in combating this disease. Therefore, it is important to establish affordable devices in laboratories with minimal infrastructure. The laser engraving technology has been revolutionary in sensor manufacturing, primarily attributed to the diversity of substrates that can be employed and the freedom it provides in creating sensor models. In this work, electrochemical sensors based on graphene were developed using the laser engraving technology for IVM sensing. Through, the studies that used the techniques of cyclic voltammetry and differential pulse voltammetry, following parameter optimization, for the laser-induced graphene electrode demonstrated a mass transport governed by adsorption of the species and exhibited a linear working range of 10-100 (µmol L-1), a limit of detection (LOD) of 1.6 × 10-6 (mol L-1), a limit of quantification (LOQ) of 4.8 × 10-6 (mol L-1), and a sensitivity of 0.139 (µA µmol L-1). The developed method was successfully applied to direct analysis of pharmaceutical tablets, tap water (recovery of 94%) and synthetic urine samples (recovery between 97% and 113%). These results demonstrate the feasibility of the method for routine analyses involving environmental samples.

Preparation of magnetic cationic Schiff base polymeric material for highly selective enrichment of avermectins from surface water and milk samples.

Herein, a magnetic cationic Schiff base polymeric material (Fe3O4@SiO2-Schiff-TAPB-DA) was fabricated simply and rapidly, which was explored as a magnetic adsorbent for magnetic solid-phase extraction (MSPE) for enriching seven avermectins insecticides in surface water and milk matrices combined with ultra-high performance liquid chromatography mass spectrometry (UPLC-MS/MS). Under the optimized pretreatment and instrumental parameters, the analytes showed good linearity in the range of 0.5-200.0 ng·mL-1 with a correlation coefficient (R2) greater than 0.9990 and high precision. The limits of detection for the analytes were 0.004-0.047 µg·L-1 for surface water sample and 0.008-0.250 µg·kg-1 for milk samples. Satisfactory recoveries of spiked target compounds were in the range of 82.25- 100.87 % for surface water sample and 72.73- 119.62 % for milk samples. The results indicated powerfully Fe3O4@SiO2-Schiff-TAPB-DA was of significant potential as an MSPE adsorbent for the detection of avermectin insecticides in surface water and milk, which provides a quick and efficient idea for enriching avermectins insecticides in complicated matrices.

Exposure of female lobsters to sediments spiked with emamectin benzoate: Effects on eggs and larvae early development.

The salmon aquaculture industry is an important economic activity established on both the west and east coast of Canada. To control sea lice infestations, in-feed products like emamectin benzoate (EMB) are widely used. Due to its low solubility and persistence EMB can accumulate in marine sediments and be potentially bioavailable to non-target organisms from months to years. The American lobster (Homarus americanus) is a key species in the Northwest Atlantic with high economic and ecological value. It may be exposed to therapeutants considering lobster habitats overlap with aquaculture locations requiring a better understanding of the potential impact of these therapeutants through varied pathways of exposure. In this study, we investigated the exposure of gravid female lobsters to EMB spiked sediment to mimic the likely presence of these females at aquaculture sites for a 10-day period. We completed testing by assessing EMB effects on adult molting and quality, embryo hatching rates, and larval offspring quality and larval molting. Our results show that a single, 10-day exposure of ovigerous females to EMB concentrations higher than environmentally relevant values did not affect females or their offspring.

Eficácia da ivermectina e atazanavir no tempo de recuperação dos sintomas de covid-19: uma coorte prospectiva / Effectiveness of ivermectin and atazanavir on time to resolution from covid-19 symptoms: a prospective cohort / Eficacia de ivermectina y atazanavir en el tiempo hasta lá resolución de los síntomas de covid-19: una cohorte prospectiva

Objetivo: avaliar a eficácia da Ivermectina e do Atazanavir em comparação com placebo no tempo de resolução dos sintomas e no tempo de duração da doença por COVID-19. Método: estudo observacional, de coorte prospectivo, longitudinal, descritivo e analítico com pacientes sintomáticos ambulatoriais, acompanhados por 06 meses em duas Unidades Básicas de Saúde para atendimento de COVID-19 em Teresina- Piauí, Brasil, no período de novembro a abril de 2021 identificados por amostragem aleatória 1:1:1. Foram realizados exames Reverse transcription polymerase chain reaction (RT-PCR) para confirmação laboratorial da suspeita de infecção pelo novo coronavírus e avaliação sociodemográfica e clínica. Resultados: dos 87 pacientes randomizados, 62,1% (n=54) eram do sexo masculino, com média de idade de 35,1 anos, possuíam companheira (53,9%), baixa renda (50,6%), eutróficos (40,7%) e sem comorbidades de saúde (78,2%). Não houve diferença entre o tempo médio para resolução dos sintomas, que foi de 21 dias (IQR, 8-30) no grupo atazanavir, 30 dias (IQR, 5-90) no grupo ivermectina em comparação com 14 dias (IQR, 9-21) no grupo controle. No dia 180, houve resolução dos sintomas em 100% no grupo placebo, 93,9% no grupo atazanavir e 95% no grupo ivermectina. A duração mediana da doença foi de 08 dias em todos os braços do estudo. Conclusão: o tratamento com atazanavir (6 dias) e ivermectina (3 dias) não reduziu o tempo de resolução dos sintomas e nem o tempo de duração da doença entre os pacientes ambulatoriais com COVID-19 leve em comparação com o grupo placebo. Os resultados não suportam o uso de ivermectina e atazanavir para tratamento de COVID-19 leve a moderado.

Objective: to evaluate the effectiveness of Ivermectin and Atazanavir compared to placebo in the time to resolution of symptoms and duration of illness due to COVID-19. Method: observational, prospective, longitudinal, descriptive and analytical cohort study with symptomatic outpatients, followed for 06 months in two Basic Health Units for COVID-19 care in Teresina-Piauí, Brazil, from November to April 2021 identified by 1:1:1 random sampling. Reverse transcription polymerase chain reaction (RT-PCR) tests were performed for laboratory confirmation of suspected infection with the new coronavirus and sociodemographic and clinical evaluation. Results: of the 87 randomized patients, 62.1% (n=54) were male, with a mean age of 35.1 years, had a partner (53.9%), low income (50.6%), eutrophic (40.7%) and without health comorbidities (78.2%). There was no difference between the median time to resolution of symptoms, which was 21 days (IQR, 8-30) in the atazanavir group, 30 days (IQR, 5- 90) in the ivermectin group compared with 14 days (IQR, 9- 21) in the control group. At day 180, there was resolution of symptoms in 100% in the placebo group, 93.9% in the atazanavir group, and 95% in the ivermectin group. The median duration of illness was 8 days in all study arms. Conclusion: Treatment with atazanavir (6 days) and ivermectin (3 days) did not reduce the time to symptom resolution or the duration of illness among outpatients with mild COVID-19 compared to the placebo group. The results do not support the use of ivermectin and atazanavir for the treatment of mild to moderate COVID-19.

Objetivo: evaluar la efectividad de Ivermectina y Atazanavir en comparación con placebo en el tiempo de resolución de los síntomas y duración de la enfermedad por COVID-19. Método: estudio de cohorte observacional, prospectivo, longitudinal, descriptivo y analítico con pacientes ambulatorios sintomáticos, seguidos durante 06 meses en dos Unidades Básicas de Salud para atención de COVID-19 en Teresina-Piauí, Brasil, de noviembre a abril de 2021 identificados por 1:1:1 muestreo aleatorio. Se realizaron pruebas de reacción en cadena de la polimerasa con transcriptasa inversa (RT-PCR) para confirmación de laboratorio de sospecha de infección por el nuevo coronavirus y evaluación sociodemográfica y clínica. Resultados: de los 87 pacientes aleatorizados, 62,1% (n=54) eran del sexo masculino, con una edad media de 35,1 años, tenían pareja (53,9%), bajos ingresos (50,6%), eutróficos (40,7%) y sin comorbilidades de salud (78,2%). No hubo diferencia entre la mediana de tiempo hasta la resolución de los síntomas, que fue de 21 días (RIC, 8-30) en el grupo de atazanavir, 30 días (RIC, 5- 90) en el grupo de ivermectina en comparación con 14 días (RIC, 9 - 21) en el grupo control. En el día 180, hubo una resolución de los síntomas del 100 % en el grupo de placebo, del 93,9 % en el grupo de atazanavir y del 95 % en el grupo de ivermectina. La mediana de duración de la enfermedad fue de 8 días en todos los brazos del estudio. Conclusión: El tratamiento con atazanavir (6 días) e ivermectina (3 días) no redujo el tiempo de resolución de los síntomas ni la duración de la enfermedad entre los pacientes ambulatorios con COVID-19 leve en comparación con el grupo placebo. Los resultados no respaldan el uso de ivermectina y atazanavir para el tratamiento de la COVID-19 de leve a moderada.

Avaliação da associação de abamectina e ivermectina no controle das helmintoses gastrointestinais em ovinos / Evaluation of the association of abamectin and ivermectin in the control of gastrointestinal helminthes in sheep / Evaluación de la asociación de abamectina e ivermectina en el control de helmintos gastrointestinales en ovinos

A helmintose gastrointestinal em ovinos é um problema crescente, devido a presença da resistência anti-helmíntica, o que dificulta sobremaneira o controle. Assim sendo, o presente trabalho teve como objetivo testar a eficácia da associação de Abamectina e Ivermectina injetável para ovinos na concentração de 3,5% em duas propriedades norte do Paraná. As ovelhas foram randomizadas pela OPG e divididas em dois grupos, sendo T1 - Controle, T2 - associação de Abamectina e Ivermectina. Os animais foram monitorados pelo método de OPG e coprocultura no dia zero e 14, para determinar a eficácia da associação, por comparação da redução da contagem de OPG, antes e após o tratamento, e os parasitos resistentes. Os resultados encontrados foram a redução de OPG pela associação Ivermectina e Abamectina de 33,89% e 93,74% na primeira e segunda propriedade, respectivamente, demonstrando a eficácia do produto somente na segunda propriedade. Concluiu-se que a associação Abamectina e Ivermectina 3,5% pode ser utilizada em propriedades na região norte do Paraná para controle da verminose, após testes de eficácia. O parasito mais incidente e, portanto o de maior resistência encontrado na análise das larvas na coprocultura foi o Haemonchus sp.(AU)

Gastrointestinal helminthes in sheep is a growing problem due to the presence of anthelmintic resistance, which greatly complicates its control. Therefore, this study aims to test the efficiency of the combination of injectable abamectin and ivermectin in sheep at a concentration of 3.5% in two properties in the northern region of Parana. The sheep were randomly assigned by OPG and divided into two groups, where T1 - control, T2 - association of abamectin and ivermectin. The animals were monitored by the OPG method and fecal culture on day zero and fourteen to determine the effectiveness of the combination by comparing the reduction in OPG before and after treatment and the resistant parasites. Ivermectin and abamectin presented a reduction of 33.89% and 93.74% in the first and second property, respectively, demonstrating the effectiveness of the product only in the second property. It could be concluded that the association of Abamectin and Ivermectin 3.5% can be used in properties in the northern Paraná to control parasitic helminths, after efficacy tests. The most prevalent parasite and therefore, the one presenting greater resistance in the analysis of the larvae during fecal culture was Haemonchus spp.(AU)

Los helmintos gastrointestinales en ovejas es un problema creciente debido a la presencia de la resistencia antihelmíntica, lo que complica en gran medida el control. Así, este estudio ha tenido como objetivo evaluar la eficacia de la asociación de Abamectina e Ivermectina inyectable para ovejas a una concentración de 3,5% en dos propiedades al norte de Paraná. Las ovejas fueron separadas por OPG y divididas en dos grupos: T1 - control, T2 - Asociación Abamectina e Ivermectina. Los animales fueron controlados por el método OPG y coprocultura en el día cero y 14, para determinar la eficacia de la combinación, por comparación de la reducción del conteo de OPG, antes y después del tratamiento, y los parásitos resistentes. Los resultados encontrados fueron la reducción de OPG por asociación de Ivermectina y Abamectina de 33,89% y 93,74% en la primera y segunda propiedad, respectivamente, lo que demuestra la eficacia del producto sólo en la segunda propiedad. Se concluyó que la asociación Abamectina e Ivermectina 3.5% puede ser utilizada en propiedades en la región norte de Paraná para controlar gusanos, después de los ensayos de eficacia. El parásito más común y por lo tanto el de mayor resistencia encontrado en el análisis de las larvas en el cultivo fecal fue el Haemonchus spp.(AU)

Resistência à ivermectina em populações de Musca domestica (Diptera: Muscidae) provenientes de granjas de galinhas poedeiras / Resistance to ivermectin in populations of Musca domestica (Diptera: Muscidae) from poultry farms

Bioensaios concentração-resposta foram realizados com o objetivo de estudar o efeito larvicida e detectar possível resistência à ivermectina em dez populações de M. domestica provenientes de granjas de galinhas poedeiras. Para tal finalidade, o meio de cultura para larvas foi tratado com diferentes concentrações de ivermectina (0,015; 0,03; 0,06; 0,125; 0,25 e 0,5 ppm). Atividade larvicida da ivermectina e anomalias nas pupas foram detectadas. A população mais resistente à ivermectina foi Monte Mor, SP (CL= 0,262 ppm e FR= 13,1). As populações de Campinas, SP (CL= 0,141 ppm 50 50 e FR = 7,1), Promissão, SP (CL= 0,110 ppm e FR = 5,5), Santa Cruz da Conceição, SP (CL= 0,102 50 50 ppm e FR = 5,1), Holambra, SP (CL= 0,071 ppm e FR = 3,6) e Hortolândia, SP (CL= 0,068 ppm e 50 50 FR = 3,4) foram mais resistentes que as de Sumaré, SP (CL= 0,052 ppm e FR = 2,6), Sarapuí, SP (CL 50 50 = 0,050 ppm e FR = 2,5) e Itanhandu, MG (CL50 = 0,047 ppm e FR = 2,4). A população mais susceptível à ivermectina foi Grande Porto Alegre, RS (CL50 = 0,020 ppm e FR = 1,0). Os resultados indicam que a ivermectina pode ser eficaz contra larvas deM. domestica. Entretanto, resistência foi suspeitada em algumas das populações, sendo importante a realização de novos estudos nesses locais.

Larvicidal effect and resistance to ivermectin in 10 populations of Musca domestica from poultry farms was evaluated by concentration-response bioassays. For this purpose, the larval growth medium was treated with different concentrations of ivermectin (0.015, 0.03, 0.06, 0.125, 0.25 and 0.5 ppm). As a result, larvicidal activity of ivermectin was observed and some anomalies were detected in pupae. The population from Monte Mor, SP, was the most resistant to ivermectin (LC50 = 0.262 ppm and RF = 13.1). Fly populations from Campinas, SP (LC50 = 0.141 ppm and RF = 7.1), Promissão, SP (LC50 = 0.110 ppm and RF = 5.5), Santa Cruz da Conceição, SP (LC50 = 0.102 ppm and RF = 5.1), Holambra, SP (LC50 = 0.071 ppm and RF = 3.6) and Hortolândia, SP (LC50 = 0.068 ppm and RF = 3.4) were more resistant than the ones from Sumaré, SP (LC50 = 0.052 ppm and RF = 2.6), Sarapuí, SP (LC50 = 0.050 ppm and RF = 2.5), and Itanhandu, MG (LC50 = 0.047 ppm and RF = 2.4). The population most susceptible to ivermectin was that from Grande Porto Alegre, RS (LC50 = 0.020 ppm and RF = 1.0). The results indicate that ivermectin can be effective against larvae ofM. domestica. However, since resistance was suspected in some of the populations studied, it is important to carry out new studies in these places.